- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03363477
Study of Pharmacodynamic Equivalence of Enoxaparin Rovi to Clexane®, in Healthy Volunteers
Demonstration of Pharmacodynamic Equivalence of Enoxaparin Rovi (100-mg Subcutaneous Injection) to Clexane® (100-mg Subcutaneous Injection) in Healthy Volunteers
To demonstrate the pharmacodynamic (PD) equivalence of enoxaparin Rovi (100 mg/mL) 100-mg SC injection to Clexane® (100 mg/mL) 100-mg SC injection in healthy volunteers.
As secondary objective, to evaluate the safety and tolerability of enoxaparin Rovi (100 mg/mL) in healthy volunteers.
Study Overview
Detailed Description
This is a single-dose, randomized, double-blind, 2-period, 2 sequence crossover study. Subjects will be screened up to 30 days before the study begins and admitted to the clinic on Day -1 of Period 1 for baseline assessments. Before dosing on Day 1 of Period 1, subjects will be randomly assigned to a treatment sequence. Subjects will receive a single dose of study drug on Day 1 of each treatment period.
On Day 1 of Period 1, subjects will receive a single dose by subcutaneous route of the assigned study drug: enoxaparin (100 mg/mL) 100-mg SC injection manufactured by Rovi Spain, or Clexane (100 mg/mL) 100-mg SC injection manufactured by Sanofi EU; after an overnight fasting period of at least 10 hours. Subjects will continue fasting for at least 4 hours after study drug administration.
The washout period between administrations of study drug in each period will be at least 7 days.
On Day 1 of Period 2, subjects will cross over to receive the dose of the other drug, after an overnight fasting period of at least 10 hours. The total duration of the study will be approximately 6 weeks.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject provides informed consent (approved by an Independent Ethical Committee (IEC)) before any study specific evaluation is performed.
- Subject is between the ages of 18 and 45 years, inclusive.
- All female subjects must have a negative pregnancy test at Screening and upon check-in to the clinic.
- Women of childbearing potential must use or have used one of the following acceptable birth control methods: Surgical sterilization (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) for at least 6 months before the first dose of study drug;Intrauterine device in place for at least 3 months before the first dose of study drug; or barrier method (condom, diaphragm) for at least 21 days before the first dose of study drug and throughout the study.
- Subject has a body mass index between 18 and 30 kg/m2, inclusive.
- Subject is able and willing to abstain from alcohol from 48 hours before the first dose of study drug through the end of the study.
- Subject has no clinically significant abnormalities in medical history, vital sign measurements, or physical examination findings.
- Subject has computerized 12-lead electrocardiogram (ECG) results showing no signs of clinically relevant pathology or deviations, as judged by the investigator.
- Subject has hematology, serum chemistry, coagulation, and urinalysis test results within the reference ranges (Hb ≥7.5 mmol/L and ≥8.5 mmol/L for female and male, respectively) or showing no clinically relevant deviations, as judged by the investigator. Thrombocytes at screening have to be within the normal range.
- Subject is a nonsmoker or has quit smoking at least 6 months before the first dose of study drug.
Exclusion Criteria:
Subjects are excluded from the study if any of the following criteria are met:
- Subject has active or recurring clinically significant skin, head, ears, eyes, nose, throat, respiratory, cardiovascular, gastrointestinal, endocrine/metabolic, genitourinary, neurologic, hematologic, musculoskeletal, immunologic, allergic, psychological/psychiatric, or other disease requiring medical treatment.
- Female subject with weight < 45 kg or male subject with weight < 57 kg.
- Subject is a woman who is pregnant or breastfeeding.
- Subject has systolic blood pressure greater than 150 mm Hg or diastolic blood pressure greater than 90 mm Hg at Screening (confirmed upon repeat measurement).
- Subject has a calculated (Cockroft & Gault formula) creatinine clearance less than 80 mL/minute and the value does not return to within reference range upon retest.
- Subject has Hb <7.5 mmol/L and <8.5 mmol/L for female and male, respectively.
- Subject has an active malignancy of any type other than nonmelanomatous skin malignancies.
- Subject has any history of alcohol abuse or drug addiction.
- Subject has any history of relevant drug and/or food allergies.
- Subject has used an investigational drug within 60 days before the first dose of study drug.
- Subject has used any prescription drugs (with special attention to antiplatelet or anticoagulant medication, eg, acetyl salicylic acid, NSADs, clopidogrel, warfarin, acenocumarol, heparin, low molecular weight heparin, dabigatran, rivaroxaban, apixaban) or over-the-counter medication that may affect coagulation (including aspirin or NSAIDs) within 4 weeks before dosing, or any other over-the-counter medication (including vitamins, herbal supplements, or dietary supplements) within 2 weeks before dosing.
- Subject has donated or lost 550 mL or more of blood (including plasmapheresis) within 60 days before the first dose of study drug.
- Subject has a positive test result for drugs of abuse (opiates, methadone, cocaine, amphetamines, cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants, oxycodone), cotinine, or alcohol.
- Subject has a positive test result for human immunodeficiency virus (1 or 2) antibody, hepatitis B surface antigen, or hepatitis C virus antibody.
- Subject has any illness within 5 days before the first dose of study drug.
- Subject has a positive test for fecal occult blood at Screening.
- Subject has any history and/or current conditions of bleeding tendency such as: active bleeding, known bleeding diathesis or hemostatic defects due to severe hepatic or renal disease; recent gastrointestinal or genitourinary bleeding (10 days before study entry) women of child-bearing potential with normal cyclic bleeding which is not considered as heavy menstruation by the investigator, are allowed for inclusion; diabetic hemorrhagic retinopathy, or other hemorrhagic ophthalmic conditions.
- Subject has a known history or family history of any relevant congenital or acquired coagulation disorder (eg, hemophilia, von Willebrand-Jürgens syndrome, or activated protein C resistance based upon Factor V Leiden mutation).
- Subject has a history of thrombocytopenia, including heparin induced thrombocytopenia.
- Subject has a known history of hypersensitivity to drugs with a similar chemical structure to enoxaparin sodium (eg, unfractionated heparin, low molecular weight heparin) or to pork products.
- Subject is a member of the professional or ancillary personnel involved in the study.
- Subject is deemed not suitable for entry into the study in the opinion of the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AB treatment sequence
Period 1-Test Treatment A: enoxaparin (100 mg/mL) 100-mg SC injection, manufactured by Rovi (Spain) Period 2-Reference Treatment B: Clexane (100 mg/mL) 100-mg SC injection, manufactured by Sanofi (EU)
|
Other Names:
Other Names:
|
Active Comparator: BA treatment sequence
Period 1-Reference Treatment B: Clexane (100 mg/mL) 100-mg SC injection, manufactured by Sanofi (EU) Period 2-Test Treatment A: enoxaparin (100 mg/mL) 100-mg SC injection, manufactured by Rovi (Spain)
|
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUEC0-inf for anti-FXa
Time Frame: Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)
|
area under the effect curve (AUEC) from time 0 to infinity, for anti-FXa
|
Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)
|
AUEC0-T for anti-FXa and anti-FIIa
Time Frame: Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)
|
area under the effect curve (AUEC) from time 0 to the last measured activity (T), for anti-FXa and anti-FIIa
|
Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)
|
Amax for anti-FXa and anti-FIIa
Time Frame: Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)
|
peak effect for anti-FXa activity (anti-FXamax), and anti-FIIa activity (anti-FIIamax)
|
Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
RAUEC
Time Frame: Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)
|
ratio of AUEC0-T of anti-FXa to anti-FIIa
|
Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)
|
Amax for TFPI levels
Time Frame: Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)
|
peak effect activity (Amax) forTissue factor pathway inhibitor (TFPI)
|
Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)
|
AUEC0-T for TFPI levels
Time Frame: Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)
|
Area under the effect curve (AUEC) from time 0 to the last measured activity (T) forTissue factor pathway inhibitor (TFPI)
|
Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)
|
AUEC0-inf for TFPI levels
Time Frame: Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)
|
Area under the effect curve (AUEC) from time 0 to infinity forTissue factor pathway inhibitor (TFPI)
|
Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)
|
Tmax for anti-FXa and anti-FIIa
Time Frame: Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)
|
time of observed maximum measured plasma activity for anti-FXa and anti-FIIa
|
Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)
|
t1/2 for anti-FXa and anti-FIIa
Time Frame: Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)
|
apparent first order terminal elimination half-life for anti-FXa and anti-FIIa
|
Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)
|
CL/F for anti-FXa and anti-FIIa
Time Frame: Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)
|
apparent plasma clearance after extravascular administration for anti-FXa and anti-FIIa
|
Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)
|
MRT for anti-FXa and anti-FIIa
Time Frame: Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)
|
mean residence time for anti-FXa and anti-FIIa
|
Day -1 (Periods 1 and 2), before dosing (Pre-dose), and between 0.5 and 36 hours after dosing on Day 1 (Periods 1 and 2)
|
Adverse Events (AEs)
Time Frame: from Informed Consent signature until 14 days after the last study drug administration (independently of the period)
|
All treatment emergent AEs (TEAEs), relationship of TEAEs to study drug, severity of TEAEs, treatment emergent serious AEs, relationship of treatment emergent serious AEs to study drug, and TEAEs leading to study drug discontinuation.
The frequency of TEAEs will be summarized by system organ class and preferred term
|
from Informed Consent signature until 14 days after the last study drug administration (independently of the period)
|
hematology
Time Frame: at Screening, Day -1 (Period 1 only), and Day 3 (Period 2 only) and at the follow up visit (Day 7 of Period 2 only)
|
clinical laboratory results
|
at Screening, Day -1 (Period 1 only), and Day 3 (Period 2 only) and at the follow up visit (Day 7 of Period 2 only)
|
Serum chemistry
Time Frame: at Screening, Day -1 (Period 1 only), and Day 3 (Period 2 only) and at the follow up visit (Day 7 of Period 2 only)
|
measurements of a variety of compounds in the serum layer of blood
|
at Screening, Day -1 (Period 1 only), and Day 3 (Period 2 only) and at the follow up visit (Day 7 of Period 2 only)
|
Coagulation
Time Frame: at Screening, Day -1 (Period 1 only), and Day 3 (Period 2 only) and at the follow up visit (Day 7 of Period 2 only)
|
Prothrombin time (reported in seconds) and activated partial thromboplastin time (aPTT)
|
at Screening, Day -1 (Period 1 only), and Day 3 (Period 2 only) and at the follow up visit (Day 7 of Period 2 only)
|
Urianalysis
Time Frame: at Screening, Day -1 (Period 1 only), and Day 3 (Period 2 only) and at the follow up visit (Day 7 of Period 2 only)
|
measurements of a variety of compounds in urine
|
at Screening, Day -1 (Period 1 only), and Day 3 (Period 2 only) and at the follow up visit (Day 7 of Period 2 only)
|
Blood presure
Time Frame: at Screening, Day -1 (Period 1 only), and before dosing (Pre-dose) and 0.5 hours after dosing on Day 1 (Periods 1 and 2)
|
systolic and diastolic blood presure recorded after the subject had been resting for at least 5 minutes
|
at Screening, Day -1 (Period 1 only), and before dosing (Pre-dose) and 0.5 hours after dosing on Day 1 (Periods 1 and 2)
|
Pulse rate
Time Frame: at Screening, Day -1 (Period 1 only), and before dosing (Pre-dose) and 0.5 hours after dosing on Day 1 (Periods 1 and 2)
|
recorded after the subject had been resting
|
at Screening, Day -1 (Period 1 only), and before dosing (Pre-dose) and 0.5 hours after dosing on Day 1 (Periods 1 and 2)
|
Respiratory rate
Time Frame: at Screening, Day -1 (Period 1 only), and before dosing (Pre-dose) and 0.5 hours after dosing on Day 1 (Periods 1 and 2)
|
measured subsequently to pulse rate
|
at Screening, Day -1 (Period 1 only), and before dosing (Pre-dose) and 0.5 hours after dosing on Day 1 (Periods 1 and 2)
|
Tympanic temperature
Time Frame: at Screening, Day -1 (Period 1 only), and before dosing (Pre-dose) and 0.5 hours after dosing on Day 1 (Periods 1 and 2)
|
measured subsequently to pulse rate
|
at Screening, Day -1 (Period 1 only), and before dosing (Pre-dose) and 0.5 hours after dosing on Day 1 (Periods 1 and 2)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Maria Velinova, MD, PhD, PRA Health Sciences (PRA) - Early Development Services (EDS)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ROV-RO20-2015-01
- 2015-003489-10 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on Clexane
-
Cristália Produtos Químicos Farmacêuticos Ltda.CompletedVenous ThromboembolismBrazil
-
Kartal Kosuyolu Yuksek Ihtisas Education and Research...UnknownPregnancy | Heart; Complications, Valve, ProsthesisTurkey
-
Monash Medical CentreMiddlemore Hospital, New Zealand; Prince of Wales Hospital, Sydney; Auckland... and other collaboratorsUnknownVenous Thrombosis | Pulmonary EmbolismAustralia, New Zealand
-
Melbourne HealthSanofi; National Heart Foundation, AustraliaTerminated
-
Shiraz University of Medical SciencesUnknownEmbolic StrokeIran, Islamic Republic of
-
ASST Fatebenefratelli SaccoMassimo Arquati; Riccardo Colombo; Umberto Russo; Manuela Nebuloni; Spinello AntinoriCompleted
-
HaEmek Medical Center, IsraelCompleted
-
University Hospital, GhentCompletedCOVID-19 | Critical Illness | Deep Vein Thrombosis | Anticoagulants and Bleeding DisordersBelgium
-
Yale UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingDeep Venous ThrombosisUnited States
-
TeaRx LLCCompletedTotal Knee ReplacementRussian Federation